The BioMed X Institute has launched a new global call for research proposals in collaboration with Boehringer Ingelheim.

The Company plans to continue to showcase measurable results from initiatives in development, operations, and M&A activity as ...

Strategic acquisition marks significant step to establish pan-European footprint and deepens expertise in oncology and early-phase biotech clinical trials.

Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...

Only three months after banking an eye-popping $350 million series D round, Eikon Therapeutics is blaming government funding ...

Independent Path for Growth The new agribiotech subsidiary will operate independently from SINTX’s medical device business, with its own development pipeline. This separation allows for focused ...

Dr. Aaron Carrithers brings a founder’s mindset and extensive firsthand experience, guiding biotech teams through complicated ...

Plus: Rockville man arrested for filming woman in fitting room at Montgomery mall; Montgomery College launches cybersecurity ...

Tucked away on the north edge of Jacksonville, surrounded by farm fields, sits a large facility where a small team assembles ...

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Mamaearth parent Honasa Consumer, GMR Airports, Emcure Pharma among others will also announce their quarterly results on ...

On May 16, 2024, the CDE’s official website announced that the Application would be reviewed via the priority review and approval process. This marks the fourth sac-TMT indication to go through the ...